“Advanced Renal Cell Carcinoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma Market.
The Advanced Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Advanced Renal Cell Carcinoma treatment therapies with a considerable amount of success over the years.
-
Advanced Renal Cell Carcinoma companies working in the treatment market are Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others, are developing therapies for the Advanced Renal Cell Carcinoma treatment
-
Emerging Advanced Renal Cell Carcinoma therapies in the different phases of clinical trials are- OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others are expected to have a significant impact on the Advanced Renal Cell Carcinoma market in the coming years.
-
In July 2023, The Chinese National Medical Products Administration (NMPA) has reviewed a supplemental new drug application (sNDA) aiming to obtain approval for the use of toripalimab (Tuoyi) in combination with axitinib (Inlyta) as a first-line treatment for patients diagnosed with unresectable or metastatic renal cell carcinoma (RCC). This application is backed by data derived from an interim analysis of the phase 3 RENOTORCH trial (NCT04394975), demonstrating that the combined therapy resulted in an enhanced progression-free survival (PFS) compared to the use of the single-agent sunitinib (Sutent).
-
In April 2023, During the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, Allogene Therapeutics shared interim findings from its Phase 1 TRAVERSE trial involving ALLO-316, the company’s initial AlloCAR T investigational product designed for treating solid tumors. The presented data showcased promising preliminary antitumor effects and a reassuring safety profile of the innovative anti-CD70 allogeneic CAR T-cell therapy, ALLO-316, particularly at lower dosage levels. These results suggest that this regimen could potentially serve as a new treatment option for heavily treated patients diagnosed with advanced clear cell renal cell carcinoma (ccRCC) expressing CD70.
-
In April 2023, Shanghai Junshi Biosciences Co., Ltd. has announced the completion of the pre-planned interim analysis for the RENOTORCH trial (NCT04394975). This trial, a phase 3 clinical study, is a multicenter, randomized, open-label investigation assessing the effectiveness of toripalimab combined with axitinib as a first-line treatment for patients diagnosed with intermediate to high-risk, unresectable, or distant metastatic renal cell carcinoma (RCC). The Independent Data Monitoring Committee (IDMC) has confirmed that the primary measure of progression-free survival (PFS), evaluated through an independent radiographic review, has achieved the predefined efficacy threshold.
-
In January 2023, Teon Therapeutics revealed a clinical trial collaboration agreement with Merck, specifically focusing on the combination arm of Teon’s ongoing clinical study. This study involves two arms, an open-label, dose escalation, and expansion phase. It aims to assess TT-816, Teon’s oral immune response modifier, in conjunction with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), designed for patients grappling with advanced solid tumors.
Advanced Renal Cell Carcinoma Overview
Advanced Renal Cell Carcinoma (RCC) refers to a stage of kidney cancer where the cancer has spread beyond the kidney to other parts of the body. Renal cell carcinoma originates in the lining of small tubes in the kidney and can progress to an advanced stage if it metastasizes or spreads to nearby lymph nodes or distant organs.
Get a Free Sample PDF Report to know more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight
Emerging Advanced Renal Cell Carcinoma Drugs Under Different Phases of Clinical Development Include:
-
OATD-02: Molecure S.A.
-
DS-6000a: Daiichi Sankyo
-
JANX008: Janux Therapeutics
-
NKT2152: NiKang Therapeutics
-
CMN-001: CoImmune
-
IPI-549: Infinity Pharmaceuticals
-
TQB2450: Chia Tai TianqingPharmaceutical
-
Belzutifan: Merck Sharp & Dohme
-
Atezolizumab: Hoffmann-La Roche
-
Volrustomig: AstraZeneca
-
XmAb819: Xencor
Advanced Renal Cell Carcinoma Route of Administration
Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Advanced Renal Cell Carcinoma Molecule Type
Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types, such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment
-
Advanced Renal Cell Carcinoma Assessment by Product Type
-
Advanced Renal Cell Carcinoma By Stage and Product Type
-
Advanced Renal Cell Carcinoma Assessment by Route of Administration
-
Advanced Renal Cell Carcinoma By Stage and Route of Administration
-
Advanced Renal Cell Carcinoma Assessment by Molecule Type
-
Advanced Renal Cell Carcinoma by Stage and Molecule Type
DelveInsight’s Advanced Renal Cell Carcinoma Report covers around 60+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Advanced Renal Cell Carcinoma product details are provided in the report. Download the Advanced Renal Cell Carcinoma pipeline report to learn more about the emerging Advanced Renal Cell Carcinoma therapies
Some of the key companies in the Advanced Renal Cell Carcinoma Therapeutics Market include:
Key companies developing therapies for Advanced Renal Cell Carcinoma are – Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, Teon Therapeutics, Asher Biotherapeutics, Shanghai Junshi Biosciences, Surface Oncology, ProfoundBio, Portage Biotech, Novartis Pharmaceuticals, HiFiBiO, and others.
Advanced Renal Cell Carcinoma Pipeline Analysis:
The Advanced Renal Cell Carcinoma pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Renal Cell Carcinoma Treatment.
-
Advanced Renal Cell Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Advanced Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Renal Cell Carcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies
Advanced Renal Cell Carcinoma Pipeline Market Drivers
-
Increasing Prevalence in Advanced Renal Cell Carcinoma, increase in the number of research and development activities are some of the important factors that are fueling the Advanced Renal Cell Carcinoma Market.
Advanced Renal Cell Carcinoma Pipeline Market Barriers
-
However, side-effects associated with the treatment of Advanced Renal Cell Carcinoma, cost associated with the treatment and other factors are creating obstacles in the Advanced Renal Cell Carcinoma Market growth.
Scope of Advanced Renal Cell Carcinoma Pipeline Drug Insight
-
Coverage: Global
-
Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others
-
Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others
-
Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
-
Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers
Request for Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and clinical trials
Table of Contents
1. Advanced Renal Cell Carcinoma Report Introduction
2. Advanced Renal Cell Carcinoma Executive Summary
3. Advanced Renal Cell Carcinoma Overview
4. Advanced Renal Cell Carcinoma- Analytical Perspective In-depth Commercial Assessment
5. Advanced Renal Cell Carcinoma Pipeline Therapeutics
6. Advanced Renal Cell Carcinoma Late Stage Products (Phase II/III)
7. Advanced Renal Cell Carcinoma Mid Stage Products (Phase II)
8. Advanced Renal Cell Carcinoma Early Stage Products (Phase I)
9. Advanced Renal Cell Carcinoma Preclinical Stage Products
10. Advanced Renal Cell Carcinoma Therapeutics Assessment
11. Advanced Renal Cell Carcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Renal Cell Carcinoma Key Companies
14. Advanced Renal Cell Carcinoma Key Products
15. Advanced Renal Cell Carcinoma Unmet Needs
16 . Advanced Renal Cell Carcinoma Market Drivers and Barriers
17. Advanced Renal Cell Carcinoma Future Perspectives and Conclusion
18. Advanced Renal Cell Carcinoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/